{"doi":"10.1371/journal.pone.0248729","title":"Accurate point-of-care serology tests for COVID-19","abstract":"BACKGROUND: As COVID-19 vaccines become available, screening individuals for prior COVID-19 infection and vaccine response in point-of-care (POC) settings has renewed interest. We prospectively screened at-risk individuals for SARS-CoV-2 spike and nucleocapsid protein antibodies in a POC setting to determine if it was a feasible method to identify antibody from prior infection. METHODS: Three EUA-approved lateral flow antibody assays were performed on POC finger-stick blood and compared with serum and a CLIA nucleocapsid antibody immunoassay. Variables including antibody class, time since PCR, and the assay antigen used were evaluated. RESULTS: 512 subjects enrolled, of which 104 had a COVID-19 history and positive PCR. Only three PCR-positive subjects required hospitalization, with one requiring mechanical ventilation. The POC results correlated well with the immunoassay (93-97% sensitivity) and using serum did not improve the sensitivity or specificity. CONCLUSIONS: Finger-stick, POC COVID-19 antibody testing was highly effective in identifying antibody resulting from prior infections in mildly symptomatic subjects. Using high-complexity serum immunoassays did not improve the screening outcome. Almost all individuals with COVID-19 infection produced detectable antibodies to the virus. POC antibody testing is useful as a screen for prior COVID-19 infection, and should be useful in assessing vaccine response.","journal":"PLoS ONE","year":2021,"id":176203,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":21,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9208,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":497178,"name":"Carmen Gherasim","orcid":"0009-0004-8484-6798","position":1,"is_corresponding":false},{"id":445118,"name":"Kelly O’Shea","orcid":"0000-0002-8147-4480","position":2,"is_corresponding":false},{"id":718737,"name":"David M. Manthei","orcid":null,"position":3,"is_corresponding":false},{"id":718232,"name":"Jesse Chen","orcid":"0000-0002-7828-7019","position":4,"is_corresponding":false},{"id":718738,"name":"Don Giacherio","orcid":null,"position":5,"is_corresponding":false},{"id":226873,"name":"Jonathan P. Troost","orcid":"0000-0002-1183-8330","position":6,"is_corresponding":false},{"id":624501,"name":"James L. Baldwin","orcid":null,"position":7,"is_corresponding":false},{"id":710074,"name":"James R. Baker","orcid":"0000-0002-4478-1932","position":8,"is_corresponding":false},{"id":345349,"name":"Charles F. Schuler","orcid":"0000-0001-5656-7418","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-18T23:47:19.591542Z","pmid":"33725025","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}